SUMMIT
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Patient / Population Intervention / Exposure Comparison Outcome
In 731 patients with HFpEF and obesity, tirzepatide reduced cardiovascular death or worsening heart failure compared with placebo.
N
731
Design
Double-blind RCT
Endpoint
CV death or worsening HF event; KCCQ score (co-primary)
Relevance
2
ResultHR 0.62 for the event composite; KCCQ improved by ~ 6.9 points.
Packer M, et al. N Engl J Med. 2025;392(5):427-437. 10.1056/NEJMoa2410027
Discussion & critique
Targets the obesity phenotype of HFpEF directly. Small and event-light — the symptom (KCCQ) benefit is more robust than the hard-outcome composite.